In the last trading session, 5.86 million shares of the Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) were traded, and its beta was 1.09. Most recently the company’s share price was $0.72, and it changed around $0.04 or 5.79% from the last close, which brings the market valuation of the company to $261.49M. LXRX currently trades at a discount to its 52-week high of $2.45, offering almost -240.28% off that amount. The share price’s 52-week low was $0.28, which indicates that the current value has risen by an impressive 61.11% since then.
Lexicon Pharmaceuticals Inc stock received a consensus recommendation rating of Hold, based on a mean score of 2.00. If we narrow it down even further, the data shows that 0 out of 5 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 2 recommended LXRX as a Hold, whereas 1 deemed it a Buy, and 0 rated it as Underweight. Lexicon Pharmaceuticals Inc is expected to report earnings per share of -0.1 for the current quarter.
Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) trade information
Instantly LXRX has showed a green trend with a performance of 5.79% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 0.7600 on recent trading dayincreased the stock’s daily price by 5.26%. The company’s shares are currently down -2.51% year-to-date, but still up 4.65% over the last five days. On the other hand, Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) is 62.45% up in the 30-day period.
The consensus price target as assigned by Wall Street analysts is $6, which translates to bulls needing to increase their stock price by 88.0% from its current value. Analyst projections state that LXRX is forecast to be at a low of $6 and a high of $6.
Lexicon Pharmaceuticals Inc (LXRX) estimates and forecasts
The year-over-year growth rate is expected to be -69.95%, down from the previous year.
Consensus estimates provided by 3 financial analysts predict the company will bring in an average of 1.18M in revenue for the current quarter. 3 analysts expect Lexicon Pharmaceuticals Inc to make 1.31M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 1.13M and 1.65M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 4.72%. Forecasts for the next quarter put sales growth at -20.66%.
Lexicon Pharmaceuticals Inc earnings are expected to increase by 42.06% in 2025, but the outlook is positive 38.72% per year for the next five years.
LXRX Dividends
Lexicon Pharmaceuticals Inc’s next quarterly earnings report is expected to be released in June.
FMR LLC, with 12.4462% or 38.69 million shares worth $64.99 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund were the top two Mutual Funds as of Mar 31, 2025 . The former held 10.16 shares worth $7.31 million, making up 2.80% of all outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund held roughly 5.15 shares worth around $3.71 million, which represents about 1.42% of the total shares outstanding.
